60 Degrees Pharmaceuticals, Inc. (SXTP) · Nov 20, 2026 · Delisting
Delisting notice — Bid price below $1.00 for 30 consecutive business days; suspension set for December 1 absent appeal
60 Degrees Pharmaceuticals received a Nasdaq delisting determination and is pursuing an appeal plus another reverse split to stay listed.
60 Degrees is a small specialty-pharma company selling FDA-approved ARAKODA for malaria prevention while trying to expand tafenoquine into babesiosis and other infectious-disease indications. Its financial cushion is thin: cash was $306,191 at September 30, 2026, versus $1.51 million at year-end 2025.
The Nasdaq problem has moved from warning to formal delisting action. The company failed the $1.00 minimum-bid rule for 30 straight business days, and Nasdaq staff determined it is ineligible for the normal compliance period because it already completed reverse splits within the prior year. 〔0〕
The immediate fix is defensive, not operational progress. 60 Degrees has requested a hearing and paid the $20,000 fee, which temporarily stays the suspension, but it now needs Nasdaq approval and another reverse split to preserve its listing. The proposed December 2 split is intended only to lift the quoted share price; it does not improve the company's cash position, product demand, clinical evidence, or regulatory status. 〔1〕
This matters more because the company is already dependent on external capital. The latest quarterly filing had warned that another failure to maintain Nasdaq compliance could reduce liquidity and make it harder to raise funds, while also noting equity had fallen close to Nasdaq's separate $2.5 million requirement. The filing itself also makes clear that neither the hearing nor the reverse split is assured: 〔2〕
Bottom line: This is a meaningful setback to the financing and market-access side of 60 Degrees' story, even though its drug-development plans are unchanged. The company is not yet delisted, but staying on Nasdaq now depends on a hearing outcome and a third recent reverse-split response to the same underlying weakness.
Nasdaq Hearings Panel decision; reverse split expected December 2
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!